Role of XXXX / @entity6410 maintenance and reliever therapy: a pragmatic study.

@entity1 @entity565 @entity228 @entity134 @entity4184 @entity6410
BACKGROUND: Many studies have demonstrated the efficacy of @entity4184 / @entity6410 (BUD/FORM) for Maintenance and Reliever Therapy (SMART  ) for @entity565 control. However, there are concerns regarding its over-use and effectiveness. OBJECTIVE: To examine @entity565 control and over-use of BUD/FORM in real-life situations. METHODS: This study was a hospital-based cross-sectional and multi-center design. @entity1 were enrolled if they were >12 years old, had persistent @entity565 , had received BUD/FORM SMART for 3 months or longer, and smoked less than 10 pack-year. RESULTS: Of the 792 @entity1 who used BUD/FORM for a mean of 28.2 months, all used BUD/FORM as maintenance and only 22.2% of the @entity1 required BUD/FORM to relieve symptoms. The average inhaled @entity228 dose used was 355.3  154.9 g/day (95% CI: 344.5 to 366.1). In 792 @entity1 , constituting 2,376 @entity1 -months of observations, there was only one @entity1 who used more than 12 puffs/ day of BUD/FORM for 3 days, with a rate of 0.015 days per @entity1 per year (95%CI: 0.003 to 0.044), without reporting any adverse events. The percentage of @entity565 control according to the Asthma Control Test score of 20 or greater was 86.5% (95% CI: 84.1 to 88.9). Overall, the rates per @entity1 per year of emergency room (ER) visits and hospital admissions were 0.18 and 0.21, respectively. CONCLUSIONS: BUD/FORM SMART is effective in real-life clinical practice. On average, @entity1 who received a low dose @entity134 in the form of BUD/FORM, had a satisfactorily high proportion of @entity565 control and had a low rate of ER visits and hospitalization. BUD/FORM maintenance and reliever therapy seems to be promising as a treatment approach for persistent @entity565 in every day clinical practice.
